Clik here to view.
Australian Health Regulators Question Benefit of Xarelto Monitoring
Foreign regulators in Australia completed a review of a new class or oral anticoagulants – Xarelto, Pradaxa and Eliquis – finding little evidence to support the benefits of routine blood monitoring in...
View ArticleClik here to view.
Study: Blood Thinner Xarelto May Cross Placental Barrier
A study recently published in the American Journal of Obstetrics & Gynecology (AJOG) found results indicating that the blood thinner Xarelto (rivaroxaban) crosses the placental barrier, raising...
View ArticleClik here to view.
Xarelto Lawsuit Alleges Severe Injuries, Fatalities
Thirteen plaintiffs have filed a lawsuit against multiple defendants, claiming that Xarelto, a blood-thinning medication, caused serious and sometimes fatal internal bleeding. The lawsuit names as...
View ArticleClik here to view.
Pradaxa, Xarelto Bleeding Complications Similar to Warfarin
According to a recent study, Pradaxa and Xarelto bleeding complications may be no less prevalent than those associated with warfarin, an anticoagulant (blood thinner) that has been on the market for...
View ArticleClik here to view.
Xarelto Internal Bleeding Lawsuit Adds 5 Plaintiffs to MDL
On August 7, 2015, five plaintiffs from as many states filed a joint complaint adding a Xarelto internal bleeding lawsuit to ongoing multi-district litigation (“MDL”). There are more than 500 Xarelto...
View ArticleClik here to view.
Bellwether Trials Scheduled for Xarelto Coordinated Litigation
Four bellwether trials have been scheduled in the ongoing coordinated proceedings underway involving the blood-thinning medication Xarelto. The judge overseeing the coordination has put four trials on...
View ArticleClik here to view.
Several Claims Added to Xarelto MDL
On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known...
View ArticleClik here to view.
FDA Approval of Xarelto May Have Been Based on False Data
Thousands of Xarelto users have brought federal lawsuits against the drug’s manufacturers alleging that the anticoagulant caused uncontrollable bleeding and severe injuries.Recent reports shed light on...
View ArticleClik here to view.
Judge Stipulates Xarelto Injury Types for Bellwether Trials
The presiding judge in the coordinated Xarelto lawsuit proceedings has issued a case management order stipulating the injury categories into which cases must be grouped to be considered for potential...
View ArticleClik here to view.
Study Suggests Xarelto Presents Greater Risk for Kidney Patients
According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on...
View ArticleClik here to view.
Xarelto MDL Continues to Grow
The Xarelto multidistrict litigation in Louisiana continues to grow, as another lawsuit was added to the ongoing proceedings on February 11. Estella Roethler filed a lawsuit individually and as the...
View ArticleClik here to view.
FDA Questions Safety Study that Led to Xarelto Approval
Xarelto, a highly touted alternative to the blood-thinning medication Warfarin, has come under fire with questions about the clinical trial that led to its approval. Faulty equipment used to monitor...
View ArticleClik here to view.
ISMP Report Emphasizes High Incidence of Xarelto Injuries
A review of adverse event reporting to the FDA in 2015 conducted by the Institute for Safe Medication Practices (ISMP) has revealed that Xarelto (rivaroaban) and its side effects were connected to more...
View ArticleClik here to view.
Xarelto and Similar Drugs Caused More than 3,000 Deaths Last Year
The blood thinner Xarelto and other anticoagulants caused more than 3,000 deaths in 2016, according to a recent report by the Institute for Safe Medication Practices (ISMP). Its QuarterWatch indicates...
View ArticleClik here to view.
Xarelto Stroke Study Stopped Because Results Indicate High Bleeding Rates
A phase III clinical study exploring the use of Xarelto (rivaroxaban) in preventing strokes and embolism in recent stroke patients has been stopped because Xarelto showed no more efficacy than the...
View ArticleClik here to view.
Xarelto Makers Ordered to Pay $27.8 Million for Failure to Warn About Risks
In early December, a Philadelphia state court ruled against the makers of the anticoagulant Xarelto, ordering them to pay $27.8 million in damages due to their failure to warn patients and the medical...
View Article
